Cargando…

Advanced Imaging Techniques for Differentiating Pseudoprogression and Tumor Recurrence After Immunotherapy for Glioblastoma

Glioblastoma (GBM) is the most common malignant tumor of the central nervous system with poor prognosis. Although the field of immunotherapy in glioma is developing rapidly, glioblastoma is still prone to recurrence under strong immune intervention. The major challenges in the process of immunothera...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yan, Ma, Yiqi, Wu, Zijun, Xie, Ruoxi, Zeng, Fanxin, Cai, Huawei, Lui, Su, Song, Bin, Chen, Lei, Wu, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656432/
https://www.ncbi.nlm.nih.gov/pubmed/34899760
http://dx.doi.org/10.3389/fimmu.2021.790674
_version_ 1784612280379375616
author Li, Yan
Ma, Yiqi
Wu, Zijun
Xie, Ruoxi
Zeng, Fanxin
Cai, Huawei
Lui, Su
Song, Bin
Chen, Lei
Wu, Min
author_facet Li, Yan
Ma, Yiqi
Wu, Zijun
Xie, Ruoxi
Zeng, Fanxin
Cai, Huawei
Lui, Su
Song, Bin
Chen, Lei
Wu, Min
author_sort Li, Yan
collection PubMed
description Glioblastoma (GBM) is the most common malignant tumor of the central nervous system with poor prognosis. Although the field of immunotherapy in glioma is developing rapidly, glioblastoma is still prone to recurrence under strong immune intervention. The major challenges in the process of immunotherapy are evaluating the curative effect, accurately distinguishing between treatment-related reactions and tumor recurrence, and providing guidance for clinical decision-making. Since the conventional magnetic resonance imaging (MRI) is usually difficult to distinguish between pseudoprogression and the true tumor progression, many studies have used various advanced imaging techniques to evaluate treatment-related responses. Meanwhile, criteria for efficacy evaluation of immunotherapy are constantly updated and improved. A standard imaging scheme to evaluate immunotherapeutic response will benefit patients finally. This review mainly summarizes the application status and future trend of several advanced imaging techniques in evaluating the efficacy of GBM immunotherapy.
format Online
Article
Text
id pubmed-8656432
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86564322021-12-10 Advanced Imaging Techniques for Differentiating Pseudoprogression and Tumor Recurrence After Immunotherapy for Glioblastoma Li, Yan Ma, Yiqi Wu, Zijun Xie, Ruoxi Zeng, Fanxin Cai, Huawei Lui, Su Song, Bin Chen, Lei Wu, Min Front Immunol Immunology Glioblastoma (GBM) is the most common malignant tumor of the central nervous system with poor prognosis. Although the field of immunotherapy in glioma is developing rapidly, glioblastoma is still prone to recurrence under strong immune intervention. The major challenges in the process of immunotherapy are evaluating the curative effect, accurately distinguishing between treatment-related reactions and tumor recurrence, and providing guidance for clinical decision-making. Since the conventional magnetic resonance imaging (MRI) is usually difficult to distinguish between pseudoprogression and the true tumor progression, many studies have used various advanced imaging techniques to evaluate treatment-related responses. Meanwhile, criteria for efficacy evaluation of immunotherapy are constantly updated and improved. A standard imaging scheme to evaluate immunotherapeutic response will benefit patients finally. This review mainly summarizes the application status and future trend of several advanced imaging techniques in evaluating the efficacy of GBM immunotherapy. Frontiers Media S.A. 2021-11-25 /pmc/articles/PMC8656432/ /pubmed/34899760 http://dx.doi.org/10.3389/fimmu.2021.790674 Text en Copyright © 2021 Li, Ma, Wu, Xie, Zeng, Cai, Lui, Song, Chen and Wu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Li, Yan
Ma, Yiqi
Wu, Zijun
Xie, Ruoxi
Zeng, Fanxin
Cai, Huawei
Lui, Su
Song, Bin
Chen, Lei
Wu, Min
Advanced Imaging Techniques for Differentiating Pseudoprogression and Tumor Recurrence After Immunotherapy for Glioblastoma
title Advanced Imaging Techniques for Differentiating Pseudoprogression and Tumor Recurrence After Immunotherapy for Glioblastoma
title_full Advanced Imaging Techniques for Differentiating Pseudoprogression and Tumor Recurrence After Immunotherapy for Glioblastoma
title_fullStr Advanced Imaging Techniques for Differentiating Pseudoprogression and Tumor Recurrence After Immunotherapy for Glioblastoma
title_full_unstemmed Advanced Imaging Techniques for Differentiating Pseudoprogression and Tumor Recurrence After Immunotherapy for Glioblastoma
title_short Advanced Imaging Techniques for Differentiating Pseudoprogression and Tumor Recurrence After Immunotherapy for Glioblastoma
title_sort advanced imaging techniques for differentiating pseudoprogression and tumor recurrence after immunotherapy for glioblastoma
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656432/
https://www.ncbi.nlm.nih.gov/pubmed/34899760
http://dx.doi.org/10.3389/fimmu.2021.790674
work_keys_str_mv AT liyan advancedimagingtechniquesfordifferentiatingpseudoprogressionandtumorrecurrenceafterimmunotherapyforglioblastoma
AT mayiqi advancedimagingtechniquesfordifferentiatingpseudoprogressionandtumorrecurrenceafterimmunotherapyforglioblastoma
AT wuzijun advancedimagingtechniquesfordifferentiatingpseudoprogressionandtumorrecurrenceafterimmunotherapyforglioblastoma
AT xieruoxi advancedimagingtechniquesfordifferentiatingpseudoprogressionandtumorrecurrenceafterimmunotherapyforglioblastoma
AT zengfanxin advancedimagingtechniquesfordifferentiatingpseudoprogressionandtumorrecurrenceafterimmunotherapyforglioblastoma
AT caihuawei advancedimagingtechniquesfordifferentiatingpseudoprogressionandtumorrecurrenceafterimmunotherapyforglioblastoma
AT luisu advancedimagingtechniquesfordifferentiatingpseudoprogressionandtumorrecurrenceafterimmunotherapyforglioblastoma
AT songbin advancedimagingtechniquesfordifferentiatingpseudoprogressionandtumorrecurrenceafterimmunotherapyforglioblastoma
AT chenlei advancedimagingtechniquesfordifferentiatingpseudoprogressionandtumorrecurrenceafterimmunotherapyforglioblastoma
AT wumin advancedimagingtechniquesfordifferentiatingpseudoprogressionandtumorrecurrenceafterimmunotherapyforglioblastoma